Background: Recent randomized controlled trials (RCTs) have shown that catheter ablation of paroxysmal atrial fibrillation (AF) is associated with a lower incidence of progression to persistent AF compared with the use of antiarrhythmic drug (AAD) therapy.
Objective: This meta-analysis aimed to investigate the magnitude of the antiprogression effect of catheter ablation as well as the effect of intervention timing.
Methods: MEDLINE/EMBASE databases were searched until April 1, 2024 for RCTs comparing catheter ablation and AAD therapy for the treatment of paroxysmal AF and reporting the rate of progression to persistent AF at 3 years (PROSPERO CRD42024534288).
Results: A total of 1287 references were retrieved, of which 5 RCTs met inclusion criteria. The rate of progression to persistent AF was 8.3% (95% confidence interval [CI] 5.4-11.2, I = 67.2%) at 3 years. The 3-year rate of progression to persistent AF was significantly lower in patients randomized to catheter ablation (1.8%; 95% CI 0.3-3.3; I = 0%) compared with AAD (14.9%; 95% CI 9.3-20.5; I = 71.9%); representing a risk ratio of progression to persistent AF at 3 years of 0.15 (95% CI 0.08-0.28; I = 0%; P < .001) for catheter ablation vs AAD therapy. Catheter ablation appeared similarly efficient in reducing progression of AF when used as first-line or non-first-line therapy (risk ratio [RR] = 0.19; 95% CI 0.07-0.48 and RR = 0.13, 95% CI 0.05-0.29, respectively, P = .551).
Conclusion: The risk of progression to persistent AF at 3 years appears to be reduced by almost 7-fold in patients with paroxysmal AF treated using catheter ablation compared with patients treated using AAD therapy, regardless of the timing of the intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2024.12.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atrial Fibrillation and Cancer-Epidemiology, Mechanisms, and Management.
J Clin Med
December 2024
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Atrial fibrillation (AF) and cancer are increasingly recognized as interrelated conditions, with cancer patients showing elevated incidences of AF, and there is evidence that AF may sometimes precede cancer diagnoses. This comprehensive review investigates the epidemiology, pathophysiology, and management challenges associated with AF in cancer patients. Epidemiologically, several cancers are more closely related to increased rates of AF, including lung, colorectal, gastrointestinal, and hematologic malignancies.
View Article and Find Full Text PDFCatheter Ablation in Atrial Fibrillation: Recent Advances.
J Clin Med
December 2024
Division of Cardiology, Inova Center of Outcomes Research, Falls Church, VA 22042, USA.
Atrial fibrillation (AF) is the leading cause of arrhythmia-related morbidity and mortality. Recurrent symptoms, hospitalizations, and cost burden to patients have necessitated treatments beyond antiarrhythmic drugs (AADs) for patients with AF. Catheter ablation has proven to be effective over medical therapy alone; however the recurrence rates for atrial tachyarrhythmias post-ablation remain significant, particularly in patients with persistent and long-standing persistent AF.
View Article and Find Full Text PDFClinical Profile and Management of Wolf-Parkinson White Syndrome and Asymptomatic Pre-Excitation Carriers in Africa: A Multicenter Pan African Registry From 17 Countries.
J Cardiovasc Electrophysiol
January 2025
Douala Gyneco-obstetric and Pediatric Hospital/University of Douala, Douala, Cameroon.
Article Synopsis
- The study explores the management and diagnosis of Wolf-Parkinson White Syndrome (WPW) and asymptomatic pre-excitation in Africa, highlighting a lack of data in the region.
- Conducted in 20 centers across 17 African countries, the research involved 541 participants and focused on symptomatology, treatment approaches, and the impact of local health dynamics on care.
- Results indicated that a vast majority were diagnosed with WPW, with significant regional differences in treatment options and effectiveness, showing that Northern and Southern Africa have more advanced practices compared to other areas.
Typical Atrial Flutter: A Practical Review.
J Cardiovasc Electrophysiol
January 2025
Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
Typical atrial flutter (AFL), defined as cavotricuspid isthmus (CTI)-dependent macro-re-entrant atrial tachycardia, often causes debilitating symptoms, and is associated with increased incidence of atrial fibrillation, stroke, heart failure, and death. Typical AFL occurs in patients with atrial remodeling and shares risk factors with atrial fibrillation. It is also common in patients with a history of prior heart surgery or catheter ablation.
View Article and Find Full Text PDFIdiopathic Annular Ventricular Arrhythmias.
Arrhythm Electrophysiol Rev
December 2024
Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center Nashville, TN, US.
Idiopathic arrhythmias originating from the mitral and tricuspid annuli are commonly encountered in clinical practice. This review focuses on distinguishing features of ventricular arrhythmias arising from these structures and the importance of distinguishing idiopathic arrhythmias from those associated with structural heart disease. Each region along the mitral and tricuspid annuli (including the cardiac crux and para-Hisian region) is then discussed separately, with a particular emphasis on the ablation strategies and pitfalls for each.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!